FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1562235336> ?p ?o ?g. }

• W1562235336 endingPage "779" @default.
• W1562235336 startingPage "765" @default.
• W1562235336 abstract "This meta-analysis compares the effectiveness and safety of tumor necrosis factor α (TNF-α) antibodies (infliximab, adalimumab and certolizumab) with either a placebo or each of them in the treatment of Crohn's disease (CD).A systematic review of literature published up to November 2012 was performed and a meta-analysis of identified studies was carried out. We searched the following databases: PubMed, EMBASE, The Cochrane Library and others. Only randomized or clinical controlled trials were included.Nineteen clinical trials fulfilled the established criteria (5 studies for infliximab vs. placebo, 6 for each adalimumab or certolizumab vs. placebo and 2 comparing infliximab with adalimumab). The results of meta-analysis showed that anti-TNF therapy in patients with CD is safe and statistically significantly more effective when compared with the placebo for induction of remission at week 4 (RB = 1.90, 95% CI: 1.55-2.33, p < 0.00001), maintenance of remission at weeks 20-30 (RB = 1.86, 95% CI: 1.61-2.15, p < 0.00001) and at weeks 48-56 (RB = 2.75, 95% CI: 2.13-3.54, p < 0.00001) in patients who responded to the induction therapy and patients randomized before the induction. Anti-TNF agents were also superior to the placebo in fistula healing (during short-term induction, as well as long-term maintenance) and inducing CR-70 but not CR-100 at week 4. Moreover, the anti-TNF therapy had a significant effect on achieving both CR-70 and CR-100 during long-term maintenance.Infliximab, adalimumab and certolizumab are effective as both induction and maintenance therapy in moderate to severe Crohn's disease in adults, including patients with fistulas. The safety profile was acceptable." @default.
• W1562235336 created "2016-06-24" @default.
• W1562235336 creator A5023818598 @default.
• W1562235336 creator A5055807164 @default.
• W1562235336 creator A5081153709 @default.
• W1562235336 creator A5082517862 @default.
• W1562235336 date "2013-01-01" @default.
• W1562235336 modified "2023-10-01" @default.
• W1562235336 title "Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis" @default.
• W1562235336 cites W136759196 @default.
• W1562235336 cites W1583184559 @default.
• W1562235336 cites W1963997208 @default.
• W1562235336 cites W1964785646 @default.
• W1562235336 cites W1966122948 @default.
• W1562235336 cites W1986215651 @default.
• W1562235336 cites W1991810959 @default.
• W1562235336 cites W2008497900 @default.
• W1562235336 cites W2009025779 @default.
• W1562235336 cites W2016996348 @default.
• W1562235336 cites W2019933066 @default.
• W1562235336 cites W2024162533 @default.
• W1562235336 cites W2026116536 @default.
• W1562235336 cites W2035049298 @default.
• W1562235336 cites W2056348171 @default.
• W1562235336 cites W2086050457 @default.
• W1562235336 cites W2099599131 @default.
• W1562235336 cites W2104015736 @default.
• W1562235336 cites W2118104319 @default.
• W1562235336 cites W2120419234 @default.
• W1562235336 cites W2121609590 @default.
• W1562235336 cites W2133115874 @default.
• W1562235336 cites W2137775651 @default.
• W1562235336 cites W2152026434 @default.
• W1562235336 cites W2156098321 @default.
• W1562235336 cites W2165107045 @default.
• W1562235336 cites W2166360124 @default.
• W1562235336 cites W2168370388 @default.
• W1562235336 cites W2171341132 @default.
• W1562235336 cites W2313112409 @default.
• W1562235336 cites W2321453230 @default.
• W1562235336 cites W2326330820 @default.
• W1562235336 cites W2991792334 @default.
• W1562235336 doi "https://doi.org/10.5114/aoms.2013.38670" @default.
• W1562235336 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3832823" @default.
• W1562235336 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24273556" @default.
• W1562235336 hasPublicationYear "2013" @default.
• W1562235336 type Work @default.
• W1562235336 sameAs 1562235336 @default.
• W1562235336 citedByCount "69" @default.
• W1562235336 countsByYear W15622353362014 @default.
• W1562235336 countsByYear W15622353362015 @default.
• W1562235336 countsByYear W15622353362016 @default.
• W1562235336 countsByYear W15622353362017 @default.
• W1562235336 countsByYear W15622353362018 @default.
• W1562235336 countsByYear W15622353362019 @default.
• W1562235336 countsByYear W15622353362020 @default.
• W1562235336 countsByYear W15622353362021 @default.
• W1562235336 countsByYear W15622353362022 @default.
• W1562235336 countsByYear W15622353362023 @default.
• W1562235336 crossrefType "journal-article" @default.
• W1562235336 hasAuthorship W1562235336A5023818598 @default.
• W1562235336 hasAuthorship W1562235336A5055807164 @default.
• W1562235336 hasAuthorship W1562235336A5081153709 @default.
• W1562235336 hasAuthorship W1562235336A5082517862 @default.
• W1562235336 hasBestOaLocation W15622353361 @default.
• W1562235336 hasConcept C126322002 @default.
• W1562235336 hasConcept C141071460 @default.
• W1562235336 hasConcept C142724271 @default.
• W1562235336 hasConcept C168563851 @default.
• W1562235336 hasConcept C17991360 @default.
• W1562235336 hasConcept C204787440 @default.
• W1562235336 hasConcept C27081682 @default.
• W1562235336 hasConcept C2776215756 @default.
• W1562235336 hasConcept C2776478404 @default.
• W1562235336 hasConcept C2776694085 @default.
• W1562235336 hasConcept C2777138892 @default.
• W1562235336 hasConcept C2778283404 @default.
• W1562235336 hasConcept C2779134260 @default.
• W1562235336 hasConcept C2779280984 @default.
• W1562235336 hasConcept C2780132546 @default.
• W1562235336 hasConcept C71924100 @default.
• W1562235336 hasConcept C90924648 @default.
• W1562235336 hasConcept C95190672 @default.
• W1562235336 hasConceptScore W1562235336C126322002 @default.
• W1562235336 hasConceptScore W1562235336C141071460 @default.
• W1562235336 hasConceptScore W1562235336C142724271 @default.
• W1562235336 hasConceptScore W1562235336C168563851 @default.
• W1562235336 hasConceptScore W1562235336C17991360 @default.
• W1562235336 hasConceptScore W1562235336C204787440 @default.
• W1562235336 hasConceptScore W1562235336C27081682 @default.
• W1562235336 hasConceptScore W1562235336C2776215756 @default.
• W1562235336 hasConceptScore W1562235336C2776478404 @default.
• W1562235336 hasConceptScore W1562235336C2776694085 @default.
• W1562235336 hasConceptScore W1562235336C2777138892 @default.
• W1562235336 hasConceptScore W1562235336C2778283404 @default.
• W1562235336 hasConceptScore W1562235336C2779134260 @default.
• W1562235336 hasConceptScore W1562235336C2779280984 @default.
• W1562235336 hasConceptScore W1562235336C2780132546 @default.

• next